| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 07/29/2004 | WO2004062557A2 Pharmaceutical combination of telmisartan and atorvastatin for the prophylaxis or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases |
| 07/29/2004 | WO2004050039A3 Spirocyclic ureas, compositions containing such compounds and methods of use |
| 07/29/2004 | WO2004037173A3 Method for treating erectile dysfunction and increasing libido in men |
| 07/29/2004 | WO2004033431A3 Hydroxypyrazoles for use against metabolic-related disorders |
| 07/29/2004 | WO2004026816B1 Aromatic liver x-receptor modulators |
| 07/29/2004 | WO2004010972A3 Pellicle-resistant gelatin capsule |
| 07/29/2004 | WO2003099783A3 Tropane compounds |
| 07/29/2004 | WO2003094861A3 Bis-benzimidazoles and related compounds as potassium channel modulators |
| 07/29/2004 | WO2003090640A3 Microbial cellulose wound dressing for treating chronic wounds |
| 07/29/2004 | WO2003086317A3 Protein a compositions and methods of use |
| 07/29/2004 | WO2003075741A3 METHODS OF PREVENTING OR TREATING DISORDERS BY ADMINISTERING AN INTEGRIN αvβ3 ANTAGONIST IN COMBINATION WITH AN HMG-CoA REDUCTASE INHIBITOR OR A BISPHOSPHONATE |
| 07/29/2004 | WO2003070881A3 RNA INTERFERENCE MEDIATED INHIBITION OF PROTEIN TYPROSINE PHOSPHATASE-1B (PTP-1B) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 07/29/2004 | WO2003040107A8 Imidazole-4-carboxamide derivatives, preparation and use thereof for treatment of obesity |
| 07/29/2004 | WO2003025150A3 Lipid-associated molecules |
| 07/29/2004 | US20040147754 Novel process |
| 07/29/2004 | US20040147748 Increasing insulin secretion; type II diabetes; such as 2-(3-Chloro-4-methanesulfonyl-phenyl)-3-cyclopentyl-N-(5-methylsulfanyl-pyrazin-2-yl)-propionamide |
| 07/29/2004 | US20040147746 Such as N-{2-[2-(5-Bromo-2-methoxy-phenyl)-ethyl]-3-fluoro-benzoyl}-N'-butyl-guanidine; involuntary weight loss disorders |
| 07/29/2004 | US20040147745 Novel compounds and compositions as protease inhibitors |
| 07/29/2004 | US20040147741 Heptadecapeptide nociceptin opioid receptor modulators; pain relievers; synthesis |
| 07/29/2004 | US20040147729 useful as agents for the prevention or treatment of diabetes, diabetic complications or obesity; inhibitory activity in human SGLT2 |
| 07/29/2004 | US20040147724 for diagnosis/treatment of cancer, myeloproliferative disorders, angiogenesis, obesity, osteoporosis, non-insulin dependent diabetes, lipid metabolism disorder, hypercalcemia, hypercholestrolemia; genetic engineering |
| 07/29/2004 | US20040147714 High linear content; low molecular weight, narrow range; using alkali metal secondary amine polymerization aide |
| 07/29/2004 | US20040147614 Serotonin receptor antagonist; administering reboxetine; psychological disorders |
| 07/29/2004 | US20040147600 Mixture of drug with insulin; antidiabetic agents |
| 07/29/2004 | US20040147599 Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors |
| 07/29/2004 | US20040147596 Antidiabetic agents; immunology diseases; antiinflammatory agents |
| 07/29/2004 | US20040147593 Eating disorders; sleep disorders; obesity |
| 07/29/2004 | US20040147587 Compounds for the modulation of the glycolysis enzyme and/or transaminase complex |
| 07/29/2004 | US20040147586 Antiproliferative agents; anticancer agents; glioblastomas; antidiabetic agents; autoimmune disorders; skin disorders; antiarthritic agents; antiinflammatory agents; cardiovascular disorders |
| 07/29/2004 | US20040147573 Metalloproteinase inhibitors |
| 07/29/2004 | US20040147572 Novel pyrrolyl-thiazole derivatives |
| 07/29/2004 | US20040147571 Substituted oxazoles and thiazoles as hppar alpha agonists |
| 07/29/2004 | US20040147570 Substituted 1 and 2-naphthol mannich bases |
| 07/29/2004 | US20040147568 Obesity; dietetics; adjust density of bones, muscles |
| 07/29/2004 | US20040147567 Control appetites; obesity; eating disorders |
| 07/29/2004 | US20040147562 Controlling cell gene expression; moderate cell proliferation; anticancer agents; antiinflammatory agents; cardiovascular disorders; autoimmune disease |
| 07/29/2004 | US20040147558 Synthesis of 3-amino-thalidomide and its enantiomers |
| 07/29/2004 | US20040147557 Aryl piperidine derivatives as inducers of ldl-receptor expression |
| 07/29/2004 | US20040147538 Fused heterocyclic compounds |
| 07/29/2004 | US20040147531 Neurodegradation diseases; alzheimer's disease; down's syndrome; antidiabetic agents |
| 07/29/2004 | US20040147528 Crystal structure; antidepressants; anxiolytic agents; eating disorders; bipolar disorders; Alzheimer's disease; sleep disorders; |
| 07/29/2004 | US20040147525 Antiinflammatory agents; analgesics; antiarthritic agents |
| 07/29/2004 | US20040147512 Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 07/29/2004 | US20040147505 Neurodegradative diseases; antiinflammatory agents; analgesics; drug abuse |
| 07/29/2004 | US20040147495 Sapogenin derivatives, their synthesis and use, and methods based upon their use |
| 07/29/2004 | US20040147490 Immunosuppressants |
| 07/29/2004 | US20040147457 Mixtures of fructose and lactose as a low-calorie bulk sweetener with reduced glycemic index |
| 07/29/2004 | US20040147446 Administration of growth hormone or analogues thereof, preferably human growth hormone, in a low dose for therapy of patients in need of increasing insulin sensitivity |
| 07/29/2004 | US20040147432 Melanin-concentrating hormone analogs |
| 07/29/2004 | US20040146994 Glycosaminoglycans derived from the k5 polysaccharide having high anticoagulant and antithrombotic activity and process for their preparation |
| 07/29/2004 | US20040146967 Novel g protein-coupled receptor protein and dna thereof |
| 07/29/2004 | US20040146925 for diagnosis and targeted drug delivery for blood cancer and monitoring protein expression or activity of white blood cells in vitro |
| 07/29/2004 | US20040146888 Cystine-knot polypeptides: cloaked-2 molecules and uses thereof |
| 07/29/2004 | US20040146872 Comprises nucleotide sequences coding delta-2-enoyl-coA isomerase for use in identifying modulators for treatment and diagnosis of inflammatory, cardiovascular, skin, body weight and cancer disorders |
| 07/29/2004 | US20040146853 Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
| 07/29/2004 | US20040146549 Amino acid sequences capable of facilitating penetration across a biological barrier |
| 07/29/2004 | US20040146538 Pharmaceutical composition for oral use comprising an active principle liable to undergo a large first intestinal passage effect |
| 07/29/2004 | US20040146525 Shellfish protein |
| 07/29/2004 | US20040146468 With excipient; suppress or reduce the gustatory function, in particular as regards a bitter and/or sweet and/or acid taste |
| 07/29/2004 | CA2513300A1 Obesity-related genes |
| 07/29/2004 | CA2513277A1 Pharmaceutical combination for the prevention or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases |
| 07/29/2004 | CA2513219A1 Multivitamin regimen for renal patients |
| 07/29/2004 | CA2512813A1 Use of substituted 2-phenylbenzimidazoles as phamaceutical compositions |
| 07/29/2004 | CA2511858A1 Metastin derivative and use thereof |
| 07/29/2004 | CA2510516A1 Fused heterocyclic derivatives as ppar modulators |
| 07/29/2004 | CA2509202A1 Fused heterocyclic derivatives as ppar modulators |
| 07/28/2004 | EP1440976A1 Modified aminoacids, pharmaceuticals containing these compounds and method for their production |
| 07/28/2004 | EP1440969A1 Alpha-form or beta-form crystal of acetanilide derivative |
| 07/28/2004 | EP1440962A1 Stabilized compositions of aqueous reduced coenzyme q solution |
| 07/28/2004 | EP1440709A2 Combinations comprising cGMP PDE5 inhibitors. |
| 07/28/2004 | EP1440688A1 Peroxisome proliferator activated receptor ligands and process for producing the same |
| 07/28/2004 | EP1440091A1 Nogo receptor homologues and their use |
| 07/28/2004 | EP1440084A2 Sperm factor sequences |
| 07/28/2004 | EP1440076A1 Silicon compounds |
| 07/28/2004 | EP1440073A1 Pde9 inhibitors for treating cardiovascular disorders |
| 07/28/2004 | EP1440062A1 An efficient synthesis of 5-heteroatom-containing-pyrazoles |
| 07/28/2004 | EP1440059A1 3-azabicyclo(3.1.0)hexane derivatives as opioid receptor antagonists |
| 07/28/2004 | EP1440057A1 Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors |
| 07/28/2004 | EP1440052A1 Benzamide derivatives as antagonists of orexin receptors |
| 07/28/2004 | EP1439863A2 Mnk kinase homologous proteins involved in the regulation of energy homeostasis and organelle metabolism |
| 07/28/2004 | EP1439842A1 Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance |
| 07/28/2004 | EP1439841A2 Androgen receptor modulators and methods of use thereof |
| 07/28/2004 | EP1439838A1 Macrolides containing pharmaceutical compositions |
| 07/28/2004 | EP1439834A1 Oxindole hydrazide modulators of protein tyrosine phosphatases (ptps) |
| 07/28/2004 | EP1439833A1 Combination of liponic acid and glutamine in food and pharmaceutical products |
| 07/28/2004 | EP1439831A1 Pharmaco-dietary preparation having a nutrition-supplementing and nutrition-enhancing effect |
| 07/28/2004 | EP1439819A1 Formulation of an erodible, gastic retentive oral dosage form using in vitro disintegration test data |
| 07/28/2004 | EP1439818A1 Chewable tablet containing lysine |
| 07/28/2004 | EP1317264B1 Combination of lipoic acids and conjugated acids for treating diabetic disorders |
| 07/28/2004 | EP1226244B1 Polypeptides with non-natural primary signalling motifs |
| 07/28/2004 | EP1183042B1 Methods for treating diabetes |
| 07/28/2004 | EP1171003B1 Complete feed for fish larvae and method for preparing same |
| 07/28/2004 | EP0927183B1 Spirocyclic metalloprotease inhibitors |
| 07/28/2004 | EP0912741B1 T-cell selective interleukin-4 agonists |
| 07/28/2004 | EP0823897B1 Nicotinic acid esters and pharmaceutical compositions containing them |
| 07/28/2004 | EP0823895B1 Fatty acid esters as bioactive compounds |
| 07/28/2004 | CN1516739A Use of HMG fragments as anti-inflammatory agents |
| 07/28/2004 | CN1516705A Novel aryl fructose-1,6-bisphosphatase inhibitors |
| 07/28/2004 | CN1516699A Polymorphic forms of 1-4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
| 07/28/2004 | CN1516690A Heterocyclic derivatives and medicines |